These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19329424)

  • 21. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
    Stone M; Salonen D; Lax M; Payne U; Lapp V; Inman R
    J Rheumatol; 2001 Jul; 28(7):1605-14. PubMed ID: 11469469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
    J Rheumatol; 2016 Sep; 43(9):1704-12. PubMed ID: 27422890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Sieper J; Braun J
    Ann Rheum Dis; 2005 Oct; 64(10):1462-6. PubMed ID: 15778240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation.
    Li EK; Griffith JF; Lee VW; Wang YX; Li TK; Lee KK; Tam LS
    Rheumatology (Oxford); 2008 Sep; 47(9):1358-63. PubMed ID: 18573802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.
    Maksymowych WP; Inman RD; Salonen D; Dhillon SS; Williams M; Stone M; Conner-Spady B; Palsat J; Lambert RG
    Arthritis Rheum; 2005 Oct; 53(5):703-9. PubMed ID: 16208659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign.
    Bisson-Vaivre A; Alcaix D; Zarnitsky C; Pueyo L; Daragon A; Lanfant-Weybel K; Dacher JN; Vittecoq O; Le Loët X; Goëb V
    Joint Bone Spine; 2013 May; 80(3):280-6. PubMed ID: 23021158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
    Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.